title: Platelet-associated LIGHT (TNFSF14) mediates adhesion of platelets to human vascular endothelium.
abstract: LIGHT (TNFSF 14) belongs to the tumor necrosis factor super-family and is expressed by different types of immune cells. Recently, LIGHT was found to be associated with platelets and released upon activation. Activation of endothelial cells by recombinant LIGHT results in pro-inflammatory and pro-thrombotic changes, qualitatively comparable to effects of CD40 ligand. Given the important role of platelet-associated CD40 ligand in vascular inflammatory responses we investigated the role of LIGHT for activation of endothelium and adhesion of platelets to endothelial cells. Expression of LIGHT was detected on thrombocytes upon exposure to ADP or TRAP-1. The expression of the LIGHT receptors TR2 and LTbetaR on native human endothelial cells was confirmed by FACS analysis. LIGHT mediated adhesion of platelets to endothelium significantly, occurring both under static and dynamic flow conditions. This interaction was inhibited by a monoclonal antibody to LIGHT but not a control IgG. Moreover, in-vitro stimulation of endothelial cells with recombinant soluble human LIGHT (rhLIGHT) resulted in significantly increased transcriptional and translational upregulation of inflammatory markers ICAM-1, tissue factor (TF) and IL-8. This activation of endothelial cells by LIGHT was mediated by NFkappaB activation and qualitatively comparable to that induced by membrane-bound CD40-ligand on transfected cells. Furthermore, plasma levels of patients with myocardial infarction, in those with ST-elevation myocardial infarction (STEMI), showed increased plasma levels of LIGHT compared with healthy controls. In conclusion, platelet-associated LIGHT is involved in adhesion of platelets to endothelium while soluble LIGHT induces a pro-inflammatory state in vascular endothelial cells. LIGHT may thus be implicated in the pathogenesis of atherosclerosis and acute coronary syndrome, as evidenced by serum levels.
authors.affiliation: Innere Medizin III, Universität Heidelberg, Heidelberg, Germany.
authors.forename: Sultan
authors.initials: S
authors.lastname: Celik
authors.forename: Harald
authors.initials: H
authors.lastname: Langer
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Stellos
authors.forename: Andreas E
authors.initials: AE
authors.lastname: May
authors.forename: Vijay
authors.initials: V
authors.lastname: Shankar
authors.forename: Kerstin
authors.initials: K
authors.lastname: Kurz
authors.forename: Hugo A
authors.initials: HA
authors.lastname: Katus
authors.forename: Meinrad P
authors.initials: MP
authors.lastname: Gawaz
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Dengler
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000737:chemistry; D001792:Blood Platelets / Q000378:metabolism; D023201:CD40 Ligand / Q000378:metabolism; D002467:Cell Nucleus / Q000378:metabolism; D002469:Cell Separation; D042783:Endothelial Cells / Q000378:metabolism; D004730:Endothelium, Vascular / Q000166:cytology* / Q000378:metabolism; D005260:Female; D006801:Humans; D007249:Inflammation; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D016328:NF-kappa B / Q000378:metabolism; D010973:Platelet Adhesiveness; D011485:Protein Binding; D053326:Tumor Necrosis Factor Ligand Superfamily Member 14 / Q000378:metabolism / Q000502:physiology*
chemical_list: D000911:Antibodies, Monoclonal; D016328:NF-kappa B; C505914:TNFSF14 protein, human; D053326:Tumor Necrosis Factor Ligand Superfamily Member 14; D023201:CD40 Ligand